Fentanyl and Dexmedetomidine as adjuvant to bupivacaine in paravertebral block for postopertive analgesia
Not Applicable
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: O- Medical and SurgicalHealth Condition 3: O- Medical and SurgicalHealth Condition 4: O- Medical and Surgical
- Registration Number
- CTRI/2021/02/031164
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.ASA I /II physical status.
2.Diagnosed cases of breast cancer.
3.Scheduled for elective modified radical mastectomy under general anesthesia.
Exclusion Criteria
1.Bleeding disorders.
2.Allergy to amide-type local anesthetics.
3.Infection at the thoracic paravertebral injection site.
4.Pregnancy or breast feeding females.
5.Severe obesity (BMI >35kg/sqâ??m).
6.Psychiatric disorders.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess the efficacy of dexmedetomidine and fentanyl as adjuvant to bupivacaine for postoperative pain management by paravertebral block. <br/ ><br>2.Postoperative VAS score(on rest/movement). <br/ ><br>3.Total rescue analgesia consumption. <br/ ><br>Timepoint: Pain assessment will be done in immediate post operative (0 min),30 min,1 hr,2 hr,4 hr,6 hr,12 hr and 24 hr. <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Intra operative hemodynamic parameters like changes in heart rate and blood pressure. <br/ ><br>2.To compare the incidence of postoperative nausea and vomiting and any other side effects. <br/ ><br>Timepoint: 1st 24 hr postoperatively